• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Malignant ascites in female patients: a seven-year review.

作者信息

Wilailak S, Linasmita V, Srivannaboon S

机构信息

Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

出版信息

J Med Assoc Thai. 1999 Jan;82(1):15-9.

PMID:10087733
Abstract

Malignant ascites is common in various types of advanced cancer. Our objective was to determine the primary site and the clinical characteristics of female patients presenting with malignant ascites as well as evaluating the outcome. The authors carried out a retrospective study of 118 cases of malignant ascites diagnosed from January 1986 to December 1992 in female patients. Of the 118 cases, the primary site of the neoplasms was gynecologic in 65 cases (cervix 4, endometrium 6, ovary 52, fallopian tube 3) = 55.1 per cent, non-gynecologic 29 cases (GI 18, lymphoma 8, breast 2, kidney 1) = 24.6 per cent, and unknown 24 cases = 20.3 per cent. The mean age of patients in the gynecologic, non-gynecologic and unknown primary site was 50.4, 45.5 and 59.3 years respectively. Surgery combined with chemotherapy was the main treatment in the gynecologic group, whereas, supportive and symptomatic management was the main treatment in the unknown primary group. Treatments in non-gynecologic group were supportive and symptomatic, surgery and chemotherapy. Survival was longer in gynecologic than in the nongynecologic and the unknown primary groups. The most common primary site of malignant ascites in females was ovarian cancer. In malignant ascites in females caused by gynecologic neoplasms, the prognosis as measured by survival was better than in the non-gynecologic and the unknown primary groups.

摘要

相似文献

1
Malignant ascites in female patients: a seven-year review.
J Med Assoc Thai. 1999 Jan;82(1):15-9.
2
Peritoneovenous shunt for palliation of gynecologic malignant ascites.用于缓解妇科恶性腹水的腹腔静脉分流术。
J Am Coll Surg. 1995 Apr;180(4):472-4.
3
Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer.1990 - 2003年瑞典非生殖道转移至卵巢表现为卵巢肿瘤:与卵巢癌相比的发生率、起源及生存率
Gynecol Oncol. 2007 Apr;105(1):166-71. doi: 10.1016/j.ygyno.2006.11.005. Epub 2006 Dec 20.
4
Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series.用于复发性妇科癌症所致大肠梗阻姑息治疗的结肠直肠支架:最新系列研究
Gynecol Oncol. 2008 Mar;108(3):482-5. doi: 10.1016/j.ygyno.2007.11.035. Epub 2008 Jan 10.
5
Gynecologic cancers: factors affecting survival after pulmonary metastasectomy.妇科癌症:影响肺转移瘤切除术后生存的因素
Ann Thorac Surg. 2006 Jun;81(6):2004-7. doi: 10.1016/j.athoracsur.2006.01.068.
6
Malignant ascites: demographics, therapeutic efficacy and predictors of survival.恶性腹水:人口统计学、治疗效果及生存预测因素
Can J Oncol. 1996 Nov;6(2):474-80.
7
Primary gastrointestinal cancers presenting as gynecologic malignancies.表现为妇科恶性肿瘤的原发性胃肠道癌症。
Gynecol Oncol. 2004 Nov;95(2):388-92. doi: 10.1016/j.ygyno.2004.07.032.
8
Primary malignant large bowel lymphoma.原发性恶性大肠淋巴瘤。
Am Surg. 2002 Feb;68(2):121-6.
9
[Clinical analysis of 42 cases of primary malignant melanoma in female genital tract].42例女性生殖道原发性恶性黑色素瘤的临床分析
Zhonghua Fu Chan Ke Za Zhi. 2007 May;42(5):320-4.
10
Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies.使用术中放疗治疗复发性妇科恶性肿瘤的长期存活者。
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):504-11. doi: 10.1016/j.ijrobp.2007.03.021. Epub 2007 Jun 8.

引用本文的文献

1
Effect of paracentesis on the survival of patients with terminal cancer and ascites: a propensity score-weighted analysis of the East Asian Collaborative Cross-cultural Study to Elucidate the Dying Process.腹腔穿刺术对晚期癌症合并腹水患者生存的影响:东亚阐明死亡过程跨文化协作研究的倾向评分加权分析
Support Care Cancer. 2022 Jul;30(7):6233-6241. doi: 10.1007/s00520-022-07057-8. Epub 2022 Apr 21.
2
Management of drainage for malignant ascites in gynaecological cancer.妇科癌症恶性腹水的引流管理
Cochrane Database Syst Rev. 2019 Dec 11;12(12):CD007794. doi: 10.1002/14651858.CD007794.pub3.
3
Development and validation of the self-completed ascites impact measure to understand patient motivation for requesting a paracentesis.
用于了解患者进行腹腔穿刺术请求动机的自我完成腹水影响量表的开发与验证。
Patient Relat Outcome Meas. 2012 Jul;3:21-30. doi: 10.2147/PROM.S28179. Epub 2012 Jun 21.
4
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.血管内皮生长因子在卵巢癌生长和腹膜转移中的意义。
Cancer Metastasis Rev. 2012 Jun;31(1-2):143-62. doi: 10.1007/s10555-011-9337-5.
5
Management of drainage for malignant ascites in gynaecological cancer.妇科癌症恶性腹水的引流管理
Cochrane Database Syst Rev. 2010 Jan 20(1):CD007794. doi: 10.1002/14651858.CD007794.pub2.
6
Do concomitant ascites influence the effectiveness of palliative surgical management of pleural effusion in patients with malignancies?合并腹水是否会影响恶性肿瘤患者胸腔积液姑息性手术治疗的效果?
World J Surg. 2009 Feb;33(2):266-71. doi: 10.1007/s00268-008-9839-7.